AbbVie’s Ex-Humira Immunology Business Is Booming

25 Jul 2024

• By Jessica Merrill

The company raised 2024 revenue expectations, driven by the second quarter performance of its Humira successors Skyrizi and Rinvoq.

AbbVie released second quarter financial results • Source: Shutterstock

More from Earnings

More from Business